Skip to Content

Pharming Group 0QCO

Morningstar Rating
€0.74 −0.01 (0.83%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

0QCO is trading at a 778% premium.
Price
€0.75
Fair Value
€9.66
Uncertainty
High
1-Star Price
€3.91
5-Star Price
€8.42
Economic Moat
Grqcb
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 0QCO is a good fit for your portfolio.

Trading Information

Previous Close Price
€0.75
Day Range
€0.730.75
52-Week Range
€0.721.31
Bid/Ask
€0.72 / €0.76
Market Cap
€501.37 Mil
Volume/Avg
222,568 / 680,762

Key Statistics

Price/Earnings (Normalized)
Price/Sales
2.30
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
382

Comparables

Valuation

Metric
0QCO
MRUS
PHVS
Price/Earnings (Normalized)
Price/Book Value
2.659.502.60
Price/Sales
2.3080.46
Price/Cash Flow
Price/Earnings
0QCO
MRUS
PHVS

Financial Strength

Metric
0QCO
MRUS
PHVS
Quick Ratio
1.165.0720.11
Current Ratio
1.435.2320.53
Interest Coverage
−2.66
Quick Ratio
0QCO
MRUS
PHVS

Profitability

Metric
0QCO
MRUS
PHVS
Return on Assets (Normalized)
−3.79%−30.56%−29.37%
Return on Equity (Normalized)
−8.05%−41.70%−31.42%
Return on Invested Capital (Normalized)
−4.58%−44.08%−32.27%
Return on Assets
0QCO
MRUS
PHVS
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
FpkrdgxzqNyv$635.4 Bil
Vertex Pharmaceuticals Inc
VRTX
FyrtlhgbmPvjrhf$124.1 Bil
Regeneron Pharmaceuticals Inc
REGN
ZdkrtjbqbKbnrbzx$114.2 Bil
Moderna Inc
MRNA
DqgmlpwVvxzk$53.7 Bil
argenx SE ADR
ARGX
WbbypqmJgg$23.0 Bil
BioNTech SE ADR
BNTX
GcdpwzjrQwzs$22.2 Bil
Alnylam Pharmaceuticals Inc
ALNY
QmlkspvNngxmx$20.3 Bil
Biomarin Pharmaceutical Inc
BMRN
TmfsqrrnWhzcbj$15.9 Bil
United Therapeutics Corp
UTHR
PytfwwwnJls$12.8 Bil
Incyte Corp
INCY
WtnqpxnpQsblx$12.2 Bil

Sponsor Center